Pharmaceutical composition for preventing and treating retinal or optic nerve diseases, comprising an adenosine derivative

A pharmaceutical composition with a specific adenosine derivative addresses the need for effective treatments for retinal and optic nerve diseases by suppressing inflammation and cell death, offering protection to retinal ganglion cells.

JP7577347B2Active Publication Date: 2024-11-05FUTURE MEDICINE CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022160407
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-11-29
Filing Date
2022-10-04
Publication Date
2024-11-05
Estimated Expiration
2038-11-29

AI Technical Summary

Technical Problem

Current treatments for retinal and optic nerve diseases are limited, and there is a need for effective pharmaceutical compositions that can prevent or treat these conditions, particularly in the form of herbal medicines rather than synthetic agents.

Method used

A pharmaceutical composition containing a specific adenosine derivative, represented by chemical formula 1 or its pharmaceutically acceptable salts, is developed for oral administration or as eye drops to prevent or treat retinal and optic nerve diseases by suppressing inflammatory responses and cell death.

Benefits of technology

The adenosine derivative effectively suppresses inflammatory cytokines and cell death, providing protection to retinal ganglion cells and preventing or treating retinal and optic nerve diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577347000020
    Figure 0007577347000020
  • Figure 0007577347000021
    Figure 0007577347000021
  • Figure 0007577347000022
    Figure 0007577347000022
Patent Text Reader

Abstract

A pharmaceutical composition for preventing or treating retinal or optic nerve diseases is provided. The present invention relates to a composition comprising a compound of the formula: TIFF2023011577000028.tif4149 (A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C-C 10 a) a linear or branched C1-C5 alkyl substituted with an aryl group; b) a benzyl unsubstituted or substituted, independently or selectively, with one or more fluoro, chloro, bromo, or linear or branched C1-C4 alkoxy groups; or c) a benzyl substituted with a hydroxycarbonyl group, and Y is H or a halogen atom.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for preventing or treating a retinal disease or an optic nerve disease, which comprises an adenosine derivative. [Background technology]

[0002] Adenosine is a substance that performs many physiological functions through receptors on specific cell membranes. Extracellular adenosine acts as a neurotransmitter in many physiological systems, but generally acts to compensate for overactivity in a given organ and protect against the harmful effects of stress (Jacobson, KA et al., J. Med. Chem., 35, 407-422, 1992). This action is due in part to a negative feedback loop that reduces the energy demand of cells and increases the supply of oxygen by adenosine, which is generated by the decomposition of ATP (adenosine triphosphate) inside or outside the cell. Adenosine is important for maintaining homeostasis in essential organs such as the brain, heart, and kidneys. For example, adenosine agonists administered externally to the brain have been shown to have a neuroprotective effect, and it is also known to be involved in pain, cognition, movement, and sleep.

[0003] Adenosine receptors are currently classified into P1 and P2 receptors through pharmacological research and molecular cloning. P1 receptors act on adenosine as a substrate, while P2 receptors exert their physiological activity by acting on ATP, ADP, UTP, and UDP as substrates. Four different subtypes of adenosine receptors have been identified for P1 receptors, which are classified into A1, A2, and A3 according to their affinity for ligands, distribution in the body, and pathway of action. A2 receptors are further classified into A1, A2, and A3. 2A and A 2BThese adenosine receptors are a type of G protein-coupled receptor family, and are classified as adenosine A1, A2, and A3. 2A and A 2B Although receptors have been pharmacologically characterized using many selective ligands, the adenosine A3 receptor was the first receptor identified in 1992 (Zhou, QY, et al., Proc. Natl. Acad. Sci., USA, 89, 7432-7436, 1992), and much research has been done to identify the pathophysiological functions of this receptor.

[0004] Adenosine A1 and A2 receptor agonists are mainly adenosine derivatives and have been extensively studied as antihypertensives, antipsychotics, antiarrhythmics, fat metabolism inhibitors (diabetes treatments), and brain protectors, while their antagonists are xanthine derivatives or various bicyclic compounds conjugated to them and have been developed as asthma treatments, antidepressants, antiarrhythmics, renal protectors, Parkinson's disease treatments, intelligence development agents, etc. Nevertheless, the only ones currently on the market are adenosine itself, which is being used to treat supraventricular tachycardia, and dipyridamole, an adenosine transport inhibitor, which is being used as an adjunct to warfarin to prevent blood coagulation after cardiac surgery. The reason for this lack of smooth commercialization is that adenosine receptors are distributed throughout the body and various pharmacological effects are associated with receptor activation; that is, there are no compounds that can activate only the adenosine receptors in the desired tissues.

[0005] Among adenosine receptors, the adenosine A3 receptor is the most recently discovered receptor, and differs from the widely known adenosine A1 and A2 receptors. Its role is not fully understood, and many studies are underway to develop selective receptor modulators. 125 I]ABA(N6 -(4-amino-3-[ 125 Iodobenzyl)-adenosine, N 6 -(4-amino-3-[ 125 I]iodobenzyl)-adenosine), [ 125 I]APNEA(N 6 -2-(4-amino-3-[ 125 Iodophenyl)-ethyl adenosine, N 6 -2-(4-amino-3-[ 125 I]iodophenyl)-ethyladenosine) or [ 125 I]AB-MECA((N 6 -(4-amino-3-[ 125 Iodobenzyl)-adenosine-5'-N-methylcarboxamide, N 6 -(4-amino-3-[ 125Three radiolabeled ligands have been used: I]iodobenzyl-adenosine-5'-N-methylcarboxamide. Pharmacological studies using the radiolabeled ligand have demonstrated that when adenosine A3 receptors are expressed in Chinese Hamster Ovary (CHO) cells, A3 receptors have an inhibitory effect on adenylate cyclase, an enzyme that produces cAMP from ATP, and that when A3 receptors are activated by agonists, they activate GTP-dependent phospholipase C, an enzyme that breaks down phosphatidyl inositol in the brain to produce inositol phosphate and DAG (Ramkumar, V. et al., J. Biol. Chem., 268, 168871-168890, 1993; Abracchio, M. Pét. al., Mol.Pharmacol.,48,1038-1045,1995). This finding explains the possibility of a reaction pathway caused by A3 receptor activation in brain ischemia, because this second messenger system represents a reaction pathway of neuronal damage in brain ischemia. A3 receptor agonists also suppress the release of tumor necrosis factor TNF-α, an inflammatory mediator, and inhibit the production of MIP-1α, interleukin-12, and interferon-γ, which are also inflammatory mediators, and are known to have a protective effect not only against brain diseases such as epilepsy, but also against the heart. Inactivation of adenosine A3 receptors can cause the release of inflammatory factors such as histamine from mast cells, constrict the bronchi, and induce apoptosis in immune cells.Therefore, since adenosine A3 receptor antagonists have the potential to be developed as anti-inflammatory agents and asthma treatments, if compounds with pharmacological selectivity can be developed, it is believed that new therapeutic drugs can be developed for a variety of diseases, including asthma, inflammation, cerebral ischemia, heart disease, and cancer.

[0006] Among the substances that have been developed to date, the representative human adenosine A3 receptor agonists are the nucleosides N 6 -(3-iodobenzyl)-5'-(N-methylcarbamoyl)-adenosine(N 6 -(3-iodobenzyl)-5'-(N-methylcarbamoyl)-adenosine;IB-MECA) and N 6 -(3-iodobenzyl)-2-chloro-5'-(N-methylcarbamoyl)-adenosine(N 6 -(3-iodobenzyl)-2-chloro-5'-(N-methylcarbamoyl)-adenosine; CI-IB-MECA), which has high affinity and selectivity for adenosine A3 receptors compared to adenosine A1 and A2 receptors. On the other hand, most adenosine A3 receptor antagonists that show high affinity and selectivity are non-purine bicyclic compounds that are not nucleoside structures and show high activity at human receptors, but have weak or no activity at rat A3 receptors, so that it has been pointed out that animal testing, which is essential for the development of clinically applicable drugs, is not possible (Baraldi, PGet al., Curr. Med. Chem., 12, 1319-1329, 2005). However, compared with non-purine bicyclic compounds, nucleoside compounds have the advantage of being easy to test in animals because they show high affinity and selectivity regardless of species. Therefore, it is believed that they have great potential for development as new drugs. Therefore, it can be said that there is an urgent need to derive selective adenosine A3 receptor antagonists of this series.

[0007] Meanwhile, the retina is a transparent, thin membrane located at the innermost part of the eyeball wall and in contact with the vitreous body. It serves as the primary visual information organ, converting optical information of objects into electrical signals and transmitting images to the central visual area of ​​the brain through the optic nerve. The retina is the most sophisticated tissue in the body, consisting of over 100 million light-sensitive photoreceptor cells, over 1 million ganglion cells, which are optic nerve cells, and various nerve cells that act as wires connecting them. The macula lutea, the central part of the retina that distinguishes colors and objects and indicates visual acuity, consists of a photoreceptor cell layer and a ganglion cell layer made up of cone cells. The retina is thin, and in bright light conditions, electrical signals of images are converted into chemical signals and transmitted to the brain via the optic nerve, which is the axon of the ganglion cells. The retina other than the macula examines the periphery and plays a major role in darkness. On the other hand, if abnormalities occur in the retina due to aging or external factors, the eyesight and field of vision will gradually become impaired, leading to blindness.

[0008] Retinal diseases are largely classified into three types: retinal detachment, which is caused by abnormalities in the peripheral retinal tissues, causing the neural retina to separate from the pigment epithelium cell layer and the retina to separate from the back of the eyeball, leading to visual impairment; peripheral retinal degeneration, which causes abnormalities in the peripheral retinal tissues; and macular degeneration, which is caused by abnormalities in the macula. Once the retina is separated from the pigment epithelium layer, it cannot transmit optical information about images, and since there is no nutritional supply from the choroid, nerve cells cannot function. If this condition is left untreated, permanent retinal atrophy occurs, leading to blindness. Visual impairment, which is the main cause of blindness, is caused by retinal diseases, and is a disease that appears mainly as we age, and is caused by genetics, severe myopia, trauma, etc., and is the second most common eye disease after cataracts. Although retinal diseases are not fatal diseases that lead to death, their incidence has been increasing rapidly recently due to an increase in the elderly population as well as industrialization and changes in eating habits. Therefore, in addition to surgical methods, it is necessary to develop a composition for treating retinal diseases that can be supplied in the form of herbal medicines that we have traditionally taken, rather than in the form of therapeutic agents synthesized by artificial methods. Summary of the Invention [Problem to be solved by the invention]

[0009] An object of the present invention is to provide a pharmaceutical composition, oral administration agent or eye drop capable of effectively preventing or treating retinal diseases.

[0010] Another object of the present invention is to provide a pharmaceutical composition, oral administration agent or eye drop capable of effectively preventing or treating optic nerve diseases. [Means for solving the problem]

[0011] To achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating retinal diseases, comprising a compound represented by the following Chemical Formula 1 or a pharma- ceutically acceptable salt thereof as an active ingredient:

[0012] The present invention also provides an orally administered agent for preventing or treating a retinal disease, comprising a compound represented by the following Chemical Formula 1 or a pharma- ceutically acceptable salt thereof:

[0013] Furthermore, the present invention provides an eye drop for preventing or treating a retinal disease, comprising a compound represented by the following Chemical Formula 1 or a pharma- ceutically acceptable salt thereof:

[0014] To achieve the above-mentioned other object, the present invention provides a pharmaceutical composition for preventing or treating optic nerve diseases, comprising a compound represented by the following Chemical Formula 1 or a pharma- ceutically acceptable salt thereof as an active ingredient:

[0015] The present invention also provides an orally administered agent for preventing or treating an optic nerve disease, comprising a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0016] Furthermore, the present invention provides an eye drop for preventing or treating an optic nerve disease, comprising a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0017] [ka]

[0018] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element. Effect of the Invention

[0019] The present invention relates to a composition for preventing or treating retinal diseases or optic nerve diseases, which contains a specific adenosine derivative as an active ingredient. The adenosine derivative can suppress the expression of inflammation-related proteins, VEGF, and inflammatory cytokines in photoreceptor cells derived from mouse retina, thereby suppressing inflammatory responses and inhibiting glutamate-induced cell death. An eye drop prepared containing the same effectively protected retinal ganglion cells in an experiment using mice, and therefore can effectively prevent or treat retinal diseases or optic nerve diseases. [Brief description of the drawings]

[0020] [Figure 1] 1 shows the results of confirming changes in the expression of angiogenesis and inflammatory response-related proteins upon treatment with compound A in one example of the present invention.

[0021] [Diagram 2] FIG. 2 shows the results of confirming changes in the expression of VEGF and inflammatory cytokines upon treatment with compound A in the Example of FIG.

[0022] [Diagram 3] FIG. 2 shows the results of confirming changes in the expression of mRNA related to neovascularization and inflammatory response upon treatment with compound A in the Example of FIG.

[0023] [Figure 4] 1 shows the results of confirming the cytotoxicity of compound A treatment on photoreceptor cells derived from mouse retina in another example of the present invention.

[0024] [Diagram 5] In the example of FIG. 4, the cytoprotective effect of compound A against glutamate-induced cell death was confirmed ((n=6), (a) 30-minute pretreatment with compound A, (b) 1-hour pretreatment with compound A).

[0025] [Figure 6]FIG. 4 shows the results of the suppressive effect of compound A on cell death observed under a microscope through TUNEL assay and DAPI staining in the Example.

[0026] [Figure 7] FIG. 4 shows the results of confirming the mitochondrial protective effect of compound A in the examples ((a) JC-1 aggregates, (b) distribution of normal group cells, (c) distribution of experimental group cells treated with glutamate only, (d) distribution of experimental group cells pretreated with compound A and then treated with glutamate, (e) distribution of control group cells treated with CCCP only).

[0027] [Figure 8] FIG. 4 shows the results of confirming the inhibitory effect of compound A on caspase activity in an example ((a) activity of caspase 3 / 7, (b) activity of caspase 8).

[0028] [Figure 9-10C] (FIG. 9 and FIG. 10A to FIG. 10C) These are the results of confirming the expression changes of proteins related to cell death caused by compound A in the Example of FIG. 4 (FIG. 9(A) protein expression changes, (B) nuclear AIF protein expression changes, (C) cytoplasmic ...

[0029] [Figure 11]13 is a graph showing the results of measuring the number of retinal ganglion cells in the eyeball of a mouse according to yet another embodiment of the present invention.

[0030] [Figure 12] 12 is a photograph showing histological changes in the mouse retina observed in the embodiment of FIG. 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] The present invention will now be described in more detail.

[0032] The present invention provides a pharmaceutical composition for preventing or treating a retinal disease, comprising, as an active ingredient, a compound represented by the following Chemical Formula 1 or a pharma- ceutical acceptable salt thereof:

[0033] [ka]

[0034] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element.

[0035] In this regard, the retinal disease may be, but is not limited to, diabetic retinopathy or age-related macular disease.

[0036] Preferably, in the formula 1, A is O or S, R is methyl, ethyl, propyl, naphthylmethyl, benzyl, benzyl independently or selectively substituted with one or more substituents selected from the group consisting of fluoro, chloro, bromo, and C1-C3 alkoxy groups, or toluic acid, and Y is H or Cl.

[0037] More preferably, A is O or S, R is methyl, ethyl, 1-naphthylmethyl, benzyl, 2-chlorobenzyl, 3-fluorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 2-methoxy-5-chlorobenzyl, 2-methoxybenzyl or 3-toluic acid, and Y is H or Cl.

[0038] Preferred examples of the adenosine derivative represented by Formula 1 according to the present invention are as follows:

[0039] 1) (2R,3R,4S)-2-(2-chloro-6-(3-fluorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0040] 2) (2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0041] 3) (2R,3R,4S)-2-(6-(3-bromobenzylamino)-2-chloro-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0042] 4) (2R,3R,4S)-2-(2-chloro-6-(2-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0043] 5) (2R,3R,4S)-2-(2-chloro-6-(5-chloro-2-methoxybenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0044] 6) (2R,3R,4S)-2-(2-chloro-6-(2-methoxybenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0045] 7) (2R,3R,4S)-2-(2-chloro-6-(naphthalen-1-ylmethylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0046] 8) 3-((2-chloro-9-((2R,3R,4S)-3,4-dihydroxytetrahydrothiophen-2-yl)-9H-purin-6-ylamino)methyl)benzoic acid;

[0047] 9) 2-(2-chloro-6-methylamino-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0048] 10) (2R,3R,4S)-2-(6-(3-fluorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0049] 11) (2R,3R,4S)-2-(6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol;

[0050] 12) (2R,3R,4S)-2-(6-(3-bromobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol; and

[0051] 13) (2R,3R,4R)-2-(6-(3-bromobenzylamino)-2-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diol.

[0052] Most preferably, the compound represented by Formula 1 is a compound represented by Formula 2:

[0053] [ka] .

[0054] The present invention also provides an orally administered agent for preventing or treating a retinal disease, comprising a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0055] [ka]

[0056] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element.

[0057] In this regard, the retinal disease may be, but is not limited to, diabetic retinopathy or age-related macular degeneration.

[0058] Preferably, in the formula 1, A is O or S, R is methyl, ethyl, propyl, naphthylmethyl, benzyl, benzyl independently or selectively substituted with one or more substituents selected from the group consisting of fluoro, chloro, bromo, and C1-C3 alkoxy groups, or toluic acid, and Y is H or Cl.

[0059] More preferably, A is O or S, R is methyl, ethyl, 1-naphthylmethyl, benzyl, 2-chlorobenzyl, 3-fluorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 2-methoxy-5-chlorobenzyl, 2-methoxybenzyl or 3-toluic acid, and Y is H or Cl.

[0060] Most preferably, the compound represented by Formula 1 is a compound represented by Formula 2:

[0061] [ka] .

[0062] The present invention also provides an eye drop for preventing or treating a retinal disease, comprising a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0063] [ka]

[0064] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element.

[0065] In this regard, the retinal disease may be, but is not limited to, diabetic retinopathy or age-related macular degeneration.

[0066] Preferably, in the formula 1, A is O or S, R is methyl, ethyl, propyl, naphthylmethyl, benzyl, benzyl independently or selectively substituted with one or more substituents selected from the group consisting of fluoro, chloro, bromo, and C1-C3 alkoxy groups, or toluic acid, and Y is H or Cl.

[0067] More preferably, A is O or S, R is methyl, ethyl, 1-naphthylmethyl, benzyl, 2-chlorobenzyl, 3-fluorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 2-methoxy-5-chlorobenzyl, 2-methoxybenzyl or 3-toluic acid, and Y is H or Cl.

[0068] Most preferably, the compound represented by Formula 1 is a compound represented by Formula 2:

[0069] [ka] .

[0070] The present invention provides a pharmaceutical composition for preventing or treating optic nerve diseases, comprising, as an active ingredient, a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0071] [ka]

[0072] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element.

[0073] In this regard, the optic nerve disease may be selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy, but is not limited thereto.

[0074] Preferably, in the formula 1, A is O or S, R is methyl, ethyl, propyl, naphthylmethyl, benzyl, benzyl independently or selectively substituted with one or more substituents selected from the group consisting of fluoro, chloro, bromo, and C1-C3 alkoxy groups, or toluic acid, and Y is H or Cl.

[0075] More preferably, A is O or S, R is methyl, ethyl, 1-naphthylmethyl, benzyl, 2-chlorobenzyl, 3-fluorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 2-methoxy-5-chlorobenzyl, 2-methoxybenzyl or 3-toluic acid, and Y is H or Cl.

[0076] Most preferably, the compound represented by Formula 1 is a compound represented by Formula 2:

[0077] [ka] .

[0078] The adenosine derivative represented by Chemical Formula 1 according to the present invention can be used in the form of a pharma- ceutically acceptable salt. As the salt, acid addition salts formed with various pharma-ceutically acceptable organic or inorganic acids are useful. Suitable organic acids include, for example, carboxylic acid, phosphonic acid, sulfonic acid, acetic acid, propionic acid, octanoic acid, decanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, malic acid, tartaric acid, citric acid, glutamic acid, aspartic acid, maleic acid, benzoic acid, salicylic acid, phthalic acid, phenylacetic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, etc., and suitable inorganic acids include, for example, halogen acids such as hydrochloric acid and sulfuric acid, or phosphoric acid, etc.

[0079] The adenosine derivative represented by Chemical Formula 1 according to the present invention may include not only pharma-ceutically acceptable salts, but also any salts, hydrates, and solvates that can be prepared by conventional methods.

[0080] In addition, the pharmaceutical composition for preventing or treating retinal or optic nerve diseases according to the present invention may contain, in addition to the above-mentioned active ingredients, a pharma- ceutically acceptable carrier, excipient, or diluent for administration, such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginic acid, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0081] The pharmaceutical composition of the present invention can be formulated and used in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions by a conventional method. In particular, when the pharmaceutical composition is formulated, it is prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, or surfactant that is commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such solid preparations are prepared by mixing the compound represented by Formula 1 or a pharma- ceutical acceptable salt thereof with at least one or more excipients, such as starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. In addition to liquids for oral administration, such as liquid paraffin, various excipients, such as wetting agents, sweeteners, flavorings, and preservatives, are added to the preparation. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.

[0082] The appropriate dosage of the composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the drug form, and the administration time, but can be appropriately selected by those skilled in the art.

[0083] The present invention also provides an orally administered agent for preventing or treating an optic nerve disease, comprising a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0084] [ka]

[0085] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element.

[0086] In this regard, the optic nerve disease may be selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy, but is not limited thereto.

[0087] Preferably, in the formula 1, A is O or S, R is methyl, ethyl, propyl, naphthylmethyl, benzyl, benzyl independently or selectively substituted with one or more substituents selected from the group consisting of fluoro, chloro, bromo, and C1-C3 alkoxy groups, or toluic acid, and Y is H or Cl.

[0088] More preferably, A is O or S, R is methyl, ethyl, 1-naphthylmethyl, benzyl, 2-chlorobenzyl, 3-fluorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 2-methoxy-5-chlorobenzyl, 2-methoxybenzyl or 3-toluic acid, and Y is H or Cl.

[0089] Most preferably, the compound represented by Formula 1 is a compound represented by Formula 2:

[0090] [ka] .

[0091] The oral agent for preventing or treating retinal or optic nerve diseases is a solid or liquid formulation containing the compound represented by Formula 1 and / or a pharma- ceutical acceptable salt thereof.

[0092] Solid preparations include tablets, pills, powders, granules, capsules, etc., and liquid preparations include suspensions, oral liquids, emulsions, syrups, etc., but are not limited to these.

[0093] The oral preparation for preventing or treating a retinal disease or an optic nerve disease may further include an excipient, i.e., one or more excipients selected from the group consisting of methyl cellulose (MC), sucrose, lactose, dimethyl sulfoxide (DMSO), polyethylene glycol (PEG), magnesium stearate, calcium carbonate, gelatin, talc, distilled water (DW), liquid paraffin, etc., more preferably, one or more excipients selected from the group consisting of methyl cellulose (MC), dimethyl sulfoxide (DMSO), polyethylene glycol (PEG), and distilled water, and more preferably, 0.5 wt% methyl cellulose.

[0094] In one embodiment of the present invention, the compound represented by Chemical Formula 1 or a pharma- ceutically acceptable salt thereof in the oral preparation for preventing or treating retinal or optic nerve diseases is filled in a capsule or the like in the form of a powder or a solution dissolved in the above-mentioned excipient, but is not limited thereto.

[0095] The present invention also provides an eye drop for preventing or treating an optic nerve disease, comprising a compound represented by the following chemical formula 1 or a pharma- ceutically acceptable salt thereof:

[0096] [ka]

[0097] In the above formula 1, A is O or S, and R is a) unsubstituted or, independently or selectively, one or more C6-C 10 wherein Y is H or a halogen atom; b) benzyl which is unsubstituted or which is independently or selectively substituted with one or more fluoro, chloro, bromo or linear or branched C1-C4 alkoxy groups; or c) benzyl substituted with hydroxycarbonyl; and Y is H or a halogen element.

[0098] In this regard, the optic nerve disease may be selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy, and compressive optic neuropathy, but is not limited thereto.

[0099] Preferably, in the formula 1, A is O or S, R is methyl, ethyl, propyl, naphthylmethyl, benzyl, benzyl independently or selectively substituted with one or more substituents selected from the group consisting of fluoro, chloro, bromo, and C1-C3 alkoxy groups, or toluic acid, and Y is H or Cl.

[0100] More preferably, A is O or S, R is methyl, ethyl, 1-naphthylmethyl, benzyl, 2-chlorobenzyl, 3-fluorobenzyl, 3-chlorobenzyl, 3-bromobenzyl, 2-methoxy-5-chlorobenzyl, 2-methoxybenzyl or 3-toluic acid, and Y is H or Cl.

[0101] Most preferably, the compound represented by Formula 1 is a compound represented by Formula 2:

[0102] [ka] .

[0103] The eye drop for preventing or treating a retinal disease or an optic nerve disease may include the compound represented by Formula 1 and / or a pharma- ceutically acceptable salt thereof and an eye drop. The eye drop may include one or more selected from the group consisting of a solubilizer, a viscosity enhancer, an antioxidant, a preservative, and a buffer solution.

[0104] In one embodiment of the present invention, the eye drop is a buffer solution of pH 6.8 in which Cremophor EL, glycerin, citric acid, and methylparaben are dissolved or mixed, but is not limited thereto.

[0105] The present invention will be described in detail below with reference to examples to help the understanding of the present invention. However, the following examples are provided to more completely explain the present invention to those skilled in the art and to illustrate the contents of the present invention, and the scope of the present invention is not limited to the following examples.

[0106] <Preparation Example 1> Synthesis of adenosine derivative compounds and production of eye drops

[0107] Adenosine derivatives were synthesized according to the method disclosed in Korean Patent Registration No. 10-1396092. The adenosine derivatives synthesized were as follows: (2R,3R,4S)-2-(2-chloro-6-(3-fluorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(2-chloro-6-(3-bromobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, Diol, (2R,3R,4S)-2-(2-chloro-6-(2-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(2-chloro-6-(5-chloro-2-methoxybenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(2-chloro-6-(2-methoxybenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S) -2-(2-chloro-6-(naphthalen-1-ylmethylbenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, 3-((2-chloro-9-((2R,3S,4R)-3,4-dihydroxytetrahydrothiophene-2-yl)-9H-purin-6-ylamino)methyl)benzoic acid, 2-(2-chloro-6-methylamino-purin-9-yl)(2R,3S,4R)-tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(6-(3-fluorobenzylamino) )-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, (2R,3R,4S)-2-(6-(3-bromobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, and (2R,3R,4R)-2-(6-(3-bromobenzylamino)-2-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diol.

[0108] In the subsequent experiments, (2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol (hereinafter also referred to as "compound A") was used, and for the animal experiments, the compound A was mixed with a buffer solution of pH 6.8 in which Cremophor EL, glycerin, citric acid and methylparaben were dissolved to prepare eye drops containing the compounds at concentrations of 250 μM, 500 μM and 750 μM, respectively.

[0109] Example 1: Confirmation of angiogenesis and inflammatory response suppression effects of adenosine derivative compounds

[0110] 1. Experimental Method

[0111] 1) Production and processing of test substances

[0112] Compound A used as a test substance was prepared by dissolving in DMSO. The prepared solution was stored at -20°C until use. The test substance was treated by diluting it 1:1000 (v / v) in serum-free cell culture medium. The control group was treated with DMSO diluted 1:1000 (v / v).

[0113] 2) Analysis of intracellular protein expression levels upon treatment with test substances

[0114] To confirm the efficacy of the test substance on neovascularization-related and inflammatory responses in mouse retina-derived photoreceptor cells, cells were harvested after 24 hours of culture under various conditions, and intracellular proteins were extracted using a PRO-PREP protein extraction kit. The amount of the extracted protein was measured using a BCA protein assay kit. 40 μg of protein was separated by 10% SDS-PAGE and then attached to a PVDF membrane. The membrane with the attached protein was reacted with TBST (Tris-buffered saline with 0.1% Tween-20) containing 5% skim milk for 30 minutes, and then reacted with a primary antibody and a secondary antibody in sequence. The protein expression level was confirmed by photographing using a Fusion Fximage acquisition system. The protein expression level was analyzed and expressed as a relative value using ImageJ. Meanwhile, the antibodies and experimental conditions used for immunoblotting are summarized in Table 1 below.

[0115] [Table 1]

[0116] 3) Quantitative analysis of intracellular inflammatory cytokines upon treatment with test substances

[0117] To confirm the efficacy of the test substance on the neovascularization-related and inflammatory responses of mouse retina-derived photoreceptor cells, cells were harvested after 24 hours of culture under various conditions, and intracellular proteins were extracted using the PRO-PREP protein extraction kit. The amount of the extracted protein was measured using the BCA protein assay kit. The amount of intracellular inflammatory cytokines (TNFα, IL-1β, IL-6) was quantitatively analyzed using the respective ELISA kits.

[0118] 4) Quantitative analysis of VEGF in the medium upon treatment with the test substance

[0119] To confirm the efficacy of the test substance on the neovascularization-related response of mouse retinal photoreceptor cells, the medium of cells cultured for 24 hours under various conditions was centrifuged and collected. VEGF present in the medium was quantitatively analyzed using the Mouse VEGF Quantikine ELISA Kit.

[0120] 5) Analysis of intracellular mRNA expression levels upon treatment with test substances

[0121] To confirm the efficacy of test substances on neovascularization-related and inflammatory responses in mouse retina-derived photoreceptor cells, cells cultured for 6 hours under various conditions were treated with TRIzol solution to isolate intracellular total RNA. cDNA was synthesized from the isolated total RNA using specific primers (Table 2) for the target genes and reverse transcriptase, and the expression of related factors was confirmed. Analysis of mRNA expression levels was shown as relative values ​​using ImageJ software.

[0122] The primers and experimental conditions used in the PCR analysis are summarized in Table 2 below.

[0123] [Table 2]

[0124] 6) Statistical analysis

[0125] The measured values ​​of each experimental group were statistically analyzed using Microsoft Excel (2007). Outliers in the results of each experimental group were identified by calculating the quartiles, and a one-way analysis of variance was performed on each data, with the results shown as the mean and standard deviation. In addition, the efficacy was analyzed at a significance level of 0.05 or less using F-tests and t-tests (homogeneous and heterogeneous variances).

[0126] 2. Experimental Results

[0127] 1) Changes in expression of angiogenesis and inflammatory response-related proteins

[0128] It has been reported that when pressure is applied to photoreceptor cells derived from mouse retina, the expression of HMGB-1 increases, and when HMGB-1 is administered to photoreceptor cells, angiogenesis-related factors and inflammatory responses increase (Bohm MR et al., Lab Invest, 96, 409-427, 2016). Based on the above references, the present invention verified the efficacy of adenosine derivatives against angiogenesis and inflammatory responses caused by damage to photoreceptor cells.

[0129] After treatment with adenosine derivative Compound A and HMGB-1, the results of analyzing the changes in protein expression of angiogenesis-related factors VEGF, VEGF receptor 1, VEGF receptor 2, angiopoietin 1, and angiopoietin 2 enzymes, and inflammatory response-related factors COX2, MMP2, MMP9, ICAM1, and VCAM1 enzymes are shown in Figures 1A and 1B.

[0130] That is, Figures 1A and 1B show that the expression of angiogenesis-related factors VEGF, VEGFR1, VEGFR2 and ANG2 was significantly increased by HMGB-1 (5 μg / mL), and that the protein expression of angiogenesis-related factors, which increased in a concentration-dependent manner, was reduced by treatment with Compound A. The expression of VEGF, VEGFR2, COX2 and MMP2 proteins was significantly reduced at concentrations of Compound A of 0.5 μM or more, and the expression of VEGFR1, ANG2 and MMP9 was significantly reduced at concentrations of 0.1 μM or more. The expression of ANG1 protein was significantly increased at a concentration of 2 μM, and the expression of ICAM1 and VCAM1 protein was significantly reduced at a concentration of 2 μM.

[0131] 2) Changes in expression of VEGF and inflammatory cytokines

[0132] To confirm the efficacy of Compound A on the neovascularization-related response and inflammatory response of mouse retinal photoreceptor cells induced by HMGB-1, a quantitative analysis was performed using ELISA analysis, and as shown in Figure 2, the amount of VEGF increased by HMGB-1 was significantly reduced by 0.1 μM or more of Compound A. The amounts of intracellular inflammatory cytokines (TNFα, IL-1β, and IL-6) were all increased by HMGB-1, but TNFα was significantly reduced by treatment with Compound A at a concentration of 0.1 μM or more, and IL-1β and IL-6 were significantly reduced by treatment with Compound A at a concentration of 1 μM or more.

[0133] 3) Changes in mRNA expression related to angiogenesis and inflammatory responses

[0134] After treatment with compound A, the mRNA expression changes of angiogenesis-related factors VEGF, VEGF receptor 1, VEGF receptor 2 enzyme, and inflammatory response-related factors TNFα, IL-6, COX2, MMP2, MMP9, ICAM1 and VCAM1 enzyme were analyzed. As shown in Figures 3A and 3B, the mRNA expression of angiogenesis-related factors VEGF, VEGFR1, and VEGFR2 was significantly increased by HMGB-1. However, the mRNA expression of angiogenesis-related factors increased by treatment with compound A was decreased in a concentration-dependent manner. The expression of VEGF and VEGFR1 was significantly decreased when treated with compound A at a concentration of 0.1 μM or more, and the expression of VEGFR2 was significantly decreased at a concentration of 0.5 μM or more. Furthermore, the mRNA expression of inflammatory response-related factors TNFα, IL-6, COX2, MMP2, MMP9, ICAM1, and VCAM1 was significantly increased by HMGB-1 in the control group, but was reduced in a concentration-dependent manner by treatment with Compound A. The expression of COX2 and IL-6 was significantly suppressed by treatment with Compound A at 0.1 μM or more, and the expression of TNFα and MMP9 was significantly reduced at a concentration of 0.5 μM or more. The expression of MMP2, ICAM1, and VCAM1 was significantly reduced by treatment with Compound A at 1 μM or more.

[0135] Example 2: Protective effect of adenosine derivatives on retinal photoreceptor cells

[0136] 1. Experimental Method

[0137] 1) Production and processing of test substances

[0138] Compound A used as a test substance was prepared by dissolving it in DMSO. The prepared solution was stored at -20°C until use. In addition, 10 mg of CCCP was dissolved in 1 mL of DMSO to prepare a 50 mM CCCP solution. The prepared solution was stored at -20°C until use. The test substance was treated by diluting it 1:1000 (v / v) in serum-free cell culture medium. The control group was treated by diluting it 1:1000 (v / v) with DMSO.

[0139] 2) TUNEL analysis

[0140] Quantitative analysis of apoptotic cells is performed using DeadEnd TM The analysis was performed using a Fluorometric TUNEL System. The cells were pretreated with 1 μM compound A for 1 hour and then cultured in a medium containing 5 mM glutamic acid for 8 hours. The cells were washed twice with PBS and fixed with 10% formalin for 15 minutes. The fixed cells were exposed to 0.1% Triton X-100 for 10 minutes. The cells were reacted with fluorescent dUTP to stain the cleaved DNA, and then fixed on a slide with a mounting solution containing DAPI. The stained cells were observed under a fluorescent microscope.

[0141] 3) Caspase 3 / 7 activity analysis

[0142] The activity of intracellular caspase 3 / 7 was analyzed using the Caspase-Glo 3 / 7 assay system. Cells were pretreated with 1 μM compound A for 1 hour and then cultured in a medium containing 5 mM glutamic acid for 24 hours. The same amount of kit solution as the cell culture medium was added and reacted for 1 hour, and the luminescence generated was measured using a microplate reader to analyze the relative activity.

[0143] 4) Caspase 8 activity analysis

[0144] The activity of intracellular caspase 8 was analyzed using the Caspase-Glo 8 assay system. Cells were pretreated with 1 μM compound A for 1 hour and then cultured in a medium containing 5 mM glutamic acid for 24 hours. The same amount of kit solution as the cell culture medium was added and reacted for 1 hour, and the amount of luminescence generated was measured using a microplate reader to analyze the relative activity.

[0145] 5) Analysis of mitochondrial membrane potential

[0146] Intracellular mitochondrial membrane potential was analyzed using JC-1 reagent. Cells were pretreated with 1 μM compound A for 1 hour and then cultured in a medium containing 5 mM glutamate for 6 hours. Then, cells were treated with 5 mM JC-1 and cultured for 30 minutes. JC-1 aggregates and JC-1 monomers were analyzed using an Attune Acoustic Focusing Cytometer at excitation wavelengths of 485 ± 11 nm and 535 ± 17.5 nm and emission wavelengths of 530 ± 15 and 590 ± 17.5 nm.

[0147] 6) Analysis of intracellular protein expression levels

[0148] In order to confirm the efficacy of the test substance on neovascularization-related and inflammatory responses in mouse retina-derived photoreceptor cells, cells cultured for 24 hours under various conditions were harvested and intracellular proteins were extracted using the PRO-PREP protein extraction kit. The amount of the extracted protein was measured using the BCA protein assay kit. 40 μg of protein was separated by 10% SDS-PAGE and then attached to a PVDF membrane. The membrane with the attached protein was reacted with TBST (Tris-buffered saline with 0.1% Tween-20) containing 5% skim milk for 30 minutes, and then reacted with a primary antibody and a secondary antibody in sequence. The protein expression level was confirmed by photographing using a Fusion Fximage acquisition system. The protein expression level was analyzed and expressed as a relative value using ImageJ. Meanwhile, the antibodies and experimental conditions used in the immunoblotting analysis are summarized in Table 3 below.

[0149] [Table 3]

[0150] 7) Statistical analysis

[0151] The measured values ​​of each experimental group were statistically analyzed using IBM's SPSS 23.0. If the experimental groups had equal variances, they were analyzed using one-way analysis of variance and Tukey's test, and if they had heteroscedasticity, they were analyzed using one-way analysis of variance and Welchs t-test. Experimental groups that showed significant statistical differences from the normal group were * P < 0.05, ** P < 0.01, *** Experimental groups showing significant statistical differences from the control group treated with glutamate only, indicated with P<0.001, were # P < 0.05, ## P < 0.01, ### P<0.001.

[0152] 2. Experimental Results

[0153] 1) Cytotoxicity of glutamate

[0154] Glutamate was diluted in the medium and treated with the cultured cells at a concentration of 0 to 9 mM. After 24 hours of culture, the cells were incubated with a cell proliferation assay reagent (CellTiter96 AQ ueous The cytotoxicity of glutamate on mouse retinal photoreceptor cells was analyzed by comparing cell viability after 1 hour using the One Solution Cell Proliferation Assay Kit. As a result, it was shown that a significant decrease in cell viability was induced in a concentration-dependent manner at concentrations of 3 mM or more, as shown in Figure 4. The IC 50 The value was confirmed to be 5.1±0.5 mM.

[0155] 2) Cytoprotective effects of adenosine derivatives

[0156] The cell protective effect of Compound A against glutamate-induced cell death was confirmed. As shown in FIG. 5 (n=6), pretreatment with Compound A inhibited the inhibition of cell viability by glutamate in a concentration-dependent manner up to a concentration of 1 μM. These experimental results indicate that Compound A has a protective effect against glutamate-induced cell death. The EC 50 The (50% effective concentration) values ​​appeared to be similar at 0.31±0.08 μM and 0.35±0.06 μM for 30 min and 1 h pretreatment, respectively.

[0157] 3) Inhibitory effect of adenosine derivatives on cell death

[0158] To confirm the induction of cell death by glutamate and the inhibitory effect of compound A, cells undergoing cell death were observed under a microscope through TUNEL assay and DAPI staining. As a result, as shown in Figure 6, TUNEL-positive reactions were confirmed in many nuclei in cells treated with glutamate alone, but the number was significantly reduced in cells pretreated with compound A. These results indicate that compound A inhibits cell death induced by glutamate.

[0159] 4) Mitochondrial protection effect of adenosine derivatives

[0160] It has been reported that cell death caused by glutamate is related to mitochondrial damage. Therefore, to confirm the effect of Compound A on mitochondrial damage caused by glutamate, mitochondrial membrane potential was analyzed using a flow cytometer. As a result, it was confirmed that JC-1 aggregates were reduced in cells treated only with glutamate, as shown in FIG. 7 and Table 4 below. A similar cell distribution was also confirmed by treatment with CCCP, which induces mitochondrial damage. However, the experimental group pretreated with Compound A showed a cell distribution similar to that of the normal group. These results indicate that Compound A suppresses intracellular mitochondrial damage caused by glutamate.

[0161] [Table 4]

[0162] 5) Confirmation of caspase activity

[0163] Caspase is known to regulate cell death. Thus, the action of caspase was confirmed by cell damage caused by glutamate and the cytoprotective effect of compound A against it. As shown in Figure 8, the activity of caspase 3 / 7 (Figure 8 (a)) and caspase 8 (Figure 8 (b)) in cells treated with glutamate alone was significantly increased, and it was confirmed that the activity of caspase 3 / 7 and caspase 8 was inhibited in a concentration-dependent manner as a result of pretreatment with compound A. This result indicates that compound A inhibits cell death caused by activation of caspase.

[0164] 6) Changes in expression of cell death-related proteins

[0165] In order to confirm the efficacy of compound A against cell death caused by glutamate, the changes in cell death-related proteins AIF and cytoplasmic protein were analyzed. As a result, as shown in FIG. 9, it was confirmed that AIF and cytoplasmic protein present in mitochondria were transferred to the nucleus and cytoplasm, respectively, in cells treated with glutamate alone, and it was confirmed that the expression of AIF and cytoplasmic protein was significantly decreased in the nucleus and cytoplasm as a result of pretreatment with compound A. In other words, it was confirmed that compound A significantly inhibits the transfer change of such proteins. These results indicate that compound A inhibits mitochondrial damage, thereby inhibiting cell damage.

[0166] In addition, to confirm the mechanism of cell death caused by glutamate and the efficacy of compound A in this regard, the change in cell death-related proteins was analyzed. As a result, as shown in Figures 10A to 10C, the expression of RIP associated with cell death was significantly decreased by glutamate, but in the experimental group pretreated with compound A, it was confirmed that it increased again in a concentration-dependent manner. In addition, the expression of pBcl2, Bcl2, pBad, Bad, and BID proteins associated with mitochondrial damage was significantly changed by glutamate, but in the experimental group pretreated with compound A, it was confirmed that the expression level was restored to the normal group. Caspase 8, cleaved caspase 9, and cleaved caspase 3 were also significantly increased by glutamate, but in the experimental group pretreated with compound A, it was confirmed that they were significantly decreased. These results indicate that compound A protects cells by suppressing cell death caused by glutamate.

[0167] Example 3: Experiment on the optic nerve protection effect of eye drops containing adenosine derivatives

[0168] In order to investigate the optic nerve protecting effect of the eye drops administered by instillation of the derivative of the present invention, the following in vivo animal experiment was carried out. The eye drops prepared in Preparation Example 1 were administered by instillation to 3-month-old normal DAB 2J mice. Xalatan, an eye drop used as a glaucoma treatment, was administered in the same manner as a positive control group, and no separate treatment was performed on the experimental animals as a negative control group.

[0169] Subsequently, after 4 months, the number of retinal ganglion cells (RGC) of the experimental animals was measured and their cross sections were observed, and the results are shown in Figures 11 and 12. In Figures 11 and 12, Control represents the negative control group, Drug 250, 500 and 750 represent eye drops containing the derivative compound (compound A) at concentrations of 250 μM, 500 μM and 750 μM, respectively, and Xalatan represents the positive control group.

[0170] 11 and 12, it was confirmed that the mice administered with the eye drops containing the adenosine derivative of the present invention had an optic nerve protective effect that was dose-dependent.

[0171] As described above, certain parts of the present invention have been described in detail, but it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. That is, the substantial scope of the present invention is defined by the following claims and their equivalents.

Claims

1. A compound represented by the following chemical formula 1: 【Chemistry 1】 (In the above formula 1, A is S, R is benzyl (excluding 3-chlorobenzyl) substituted with one or more substituents selected from the group consisting of F, Br, Cl, and I, and Y is Cl. or a pharma- ceutical composition for preventing or treating a retinal disease, comprising as an active ingredient, The pharmaceutical composition, wherein the retinal disease is diabetic retinopathy or age-related macular degeneration.

2. The pharmaceutical composition for preventing or treating a retinal disease according to claim 1 , which is an orally administered agent.

3. A compound represented by the following chemical formula 1: 【Chemistry 2】 (In the above formula 1, A is S, R is benzyl (excluding 3-chlorobenzyl) substituted with one or more substituents selected from the group consisting of F, Br, Cl, and I, and Y is Cl. or a pharma- ceutical composition for preventing or treating an optic nerve disease, comprising as an active ingredient, The pharmaceutical composition, wherein the optic nerve disease is selected from the group consisting of ischemic optic neuropathy, traumatic optic neuropathy and compressive optic neuropathy.

4. The pharmaceutical composition for preventing or treating an optic nerve disease according to claim 3, which is an orally administered agent.

Citation Information

Patent Citations

  • Effective delivery of species-cross-reactive A3 adenosine receptor antagonists to lower intraocular pressure

    JP2010505848A

  • Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases

    WO2012125400A1